Total
0
Shares
BioCure Technology - Björn Cochlovius Ph.D. President - The Market Herald Canada
Björn Cochlovius Ph.D. President
Source: Isogenica
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • BioCure Technology (CURE) has appointed a new president, a Capital Markets Advisor and granted stock options
  • Björn Cochlovius, Ph.D. has joined BioCure Technology Inc. as President
  • Diverse Capital Pte Ltd. has been appointed as a Capital Markets Advisor
  • Biocure is a leading biotech company developing its CAR-T cell therapy for leukemia, lung, breast and pancreatic cancer
  • Biocure Technology Inc. (CURE) is unchanged, trading at C$0.20 per share

BioCure Technology (CURE) has appointed a new president, a Capital Markets Advisor and granted stock options to directors, employees and consultants.

Björn Cochlovius, Ph.D. has joined BioCure Technology Inc. as President. Dr. Cochlovius brings leadership experience in multiple management and board positions. He has experience in science, development and fundraising. Dr. Cochlovius is a passionate healthcare professional combining strategic vision and business acumen with a strong scientific and product development background.

Bjoern Cochlovius, Ph.D. is a Molecular Biologist and Associate Professor for Immunology at Heidelberg University, Heidelberg, Germany. His academic career focused on Tumor Immunology and Recombinant Antibodies. He has been Guest Scientist at Zelig Eshhar's lab at the Weizmann Institute, a pioneer of CAR-T cell technology. 

Diverse Capital Pte Ltd. has been appointed as a Capital Markets Advisor.

Diverse Capital was founded by Mr. Steven Pearce, who has over 20 years of experience in the Stock Brokerage, Fund Management and Capital Markets industries.

BioCure Technology Inc. has granted an aggregate of 1,250,000 stock options to certain directors, officers, employees and consultants of the company. The options are exercisable at a price of $0.30 per share for a period of up to 36 months. The options and underlying common shares are subject to a four-month hold period in accordance with the policies of the Canadian Securities Exchange.

Biocure is a leading biotech company developing its CAR-T cell therapy for leukemia, lung, breast and pancreatic cancer.

Biocure Technology Inc. (CURE) is unchanged, trading at C$0.20 per share.

More From The Market Herald
Field Trip Health - CEO, Joseph del Moral. - The Market Herald Canada

" Field Trip Health (TSX:FTRP) obtains conditional approval to list on the NASDAQ

Field Trip Health (FTRP) has obtained conditional approval to list on the NASDAQ Global Select Market under the symbol FTRP.
Skylight Health (TSXV:SHG) starts onboarding for GatherMed

" Relay Medical (CSE:RELA) Cybeats platform now supports Android OS

Relay Medical’s (RELA) has announced that its Cybeats cybersecurity platform now supports Android operating systems for IoT devices.
Levitee Labs - CEO, Pouya Farmand. - The Market Herald Canada

" Levitee Labs (CSE:LVT) goes on acquisition spree

Levitee Labs (LVT) has signed definitive agreements to acquire five clinics, three pharmacies and a telemedicine company in Alberta.
BetterLife Pharma - CEO, Ahmad Doroudian. - The Market Herald Canada

" BetterLife (CSE:BETR) partners with Carleton University to research treatment for chronic anxiety

BetterLife Pharma (BETR) has received funding for its joint research with Carleton University into the use of TD-010 to treat chronic anxiety and